PL2373293T3 - Kompozycje o ograniczonym powstawaniu dimerów - Google Patents

Kompozycje o ograniczonym powstawaniu dimerów

Info

Publication number
PL2373293T3
PL2373293T3 PL09760560T PL09760560T PL2373293T3 PL 2373293 T3 PL2373293 T3 PL 2373293T3 PL 09760560 T PL09760560 T PL 09760560T PL 09760560 T PL09760560 T PL 09760560T PL 2373293 T3 PL2373293 T3 PL 2373293T3
Authority
PL
Poland
Prior art keywords
compositions
dimer formation
reduced dimer
reduced
formation
Prior art date
Application number
PL09760560T
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2373293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of PL2373293T3 publication Critical patent/PL2373293T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL09760560T 2008-11-28 2009-11-27 Kompozycje o ograniczonym powstawaniu dimerów PL2373293T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0821806.7A GB0821806D0 (en) 2008-11-28 2008-11-28 Compositions with reduced dimer formation
PCT/GB2009/002767 WO2010061193A2 (en) 2008-11-28 2009-11-27 Compositions with reduced dimer formation
EP09760560.4A EP2373293B2 (en) 2008-11-28 2009-11-27 Compositions with reduced dimer formation

Publications (1)

Publication Number Publication Date
PL2373293T3 true PL2373293T3 (pl) 2013-12-31

Family

ID=40262373

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09760560T PL2373293T3 (pl) 2008-11-28 2009-11-27 Kompozycje o ograniczonym powstawaniu dimerów

Country Status (20)

Country Link
US (3) US9180098B2 (pl)
EP (2) EP2373293B2 (pl)
JP (2) JP5612592B2 (pl)
KR (1) KR101669693B1 (pl)
CN (1) CN102227214B (pl)
AU (1) AU2009321358B2 (pl)
BR (1) BRPI0921541A2 (pl)
CA (1) CA2744587C (pl)
DK (1) DK2373293T3 (pl)
EA (1) EA019923B1 (pl)
ES (1) ES2427855T5 (pl)
GB (2) GB0821806D0 (pl)
HR (1) HRP20130933T1 (pl)
IL (1) IL213088A (pl)
MX (1) MX2011005530A (pl)
NZ (1) NZ593145A (pl)
PL (1) PL2373293T3 (pl)
SG (1) SG171438A1 (pl)
SI (1) SI2373293T1 (pl)
WO (1) WO2010061193A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2793939A1 (en) * 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
GB201301457D0 (en) 2013-01-28 2013-03-13 Fluorogenics Ltd Freeze-dried composition
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CN103656635B (zh) * 2013-12-05 2016-05-18 安徽润敏江生物科技有限公司 一种德国小蠊过敏原制剂的制备方法
JP6762877B2 (ja) * 2014-04-10 2020-09-30 アシット バイオテック エスエー 熱ショックタンパク質を本質的に含まない医薬製剤、医薬製剤を含むバイアル又は投与具、バイアル又は投与具を含むキット、並びにアレルギーの治療方法
CN107207622B (zh) * 2015-02-04 2021-09-28 苏黎世大学 Hla-b27同二聚体用于癌症治疗的用途
WO2017083753A1 (en) 2015-11-12 2017-05-18 Herr John C Compositions and methods for vas-occlusive contraception and reversal thereof
US10925969B2 (en) 2015-11-13 2021-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Anti-BCMA polypeptides and proteins
KR102456666B1 (ko) 2016-03-08 2022-10-19 유니버시타트 취리히 ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
ES2949372T3 (es) 2016-08-10 2023-09-28 Univ Zuerich Confórmeros abiertos del CMH de clase Ia
US10751124B2 (en) 2017-01-05 2020-08-25 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
US12383421B2 (en) 2017-01-05 2025-08-12 Contraline, Inc. Contraceptive devices
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US11318040B2 (en) 2018-11-13 2022-05-03 Contraline, Inc. Systems and methods for delivering biomaterials
CA3204152A1 (en) * 2021-01-22 2022-07-28 Syngenta Crop Protection Ag Soybean engineered resistance

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4855407A (en) 1985-04-11 1989-08-08 Alpha-1 Biomedicals, Inc. Solid phase process for synthesizing peptides
JP2787162B2 (ja) * 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
CA2073045C (en) * 1989-11-03 2007-05-22 Malcolm L. Gefter A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1993008279A1 (en) 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07507924A (ja) 1992-04-09 1995-09-07 イミュロジック　ファーマスーティカル　コーポレイション アンブロシア・アルテミシフォリア由来の主要アレルゲンのｔ細胞エピトープ
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
DE69333985T2 (de) 1992-12-31 2006-11-23 Immulogic Pharmaceutical Corp., Waltham Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
AU7726094A (en) 1994-09-02 1996-03-27 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
JP2001526239A (ja) * 1997-12-22 2001-12-18 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
EP1044019A1 (en) * 1998-01-09 2000-10-18 Circassia Limited Methods and compositions for desensitisation
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
JP2005521640A (ja) 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
ATE414534T1 (de) 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
WO2003077937A1 (en) * 2002-03-15 2003-09-25 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
EP1523326A4 (en) 2002-05-06 2009-09-09 Univ Jefferson INSULIN-ASSOCIATED PEPTIDES FOR IMPROVING BRAIN EFFECT
JP2007534633A (ja) 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
PL1559431T3 (pl) 2003-12-31 2007-10-31 Orthologic Corp Kompozycja farmaceutyczna dla pochodnych peptydu trombiny
JP2007277094A (ja) 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
SG160336A1 (en) * 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20090155351A1 (en) * 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
EP2286833A3 (en) * 2007-08-15 2011-09-14 Circassia Limited Peptides for desensibilization against allergens
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation

Also Published As

Publication number Publication date
ES2427855T3 (es) 2013-11-04
EA019923B1 (ru) 2014-07-30
KR101669693B1 (ko) 2016-11-09
JP5905942B2 (ja) 2016-04-20
AU2009321358A1 (en) 2011-06-30
US20160038587A1 (en) 2016-02-11
CA2744587C (en) 2020-07-14
GB0821806D0 (en) 2009-01-07
JP2012510457A (ja) 2012-05-10
EP2649990A1 (en) 2013-10-16
HRP20130933T1 (hr) 2013-11-08
KR20110092329A (ko) 2011-08-17
US20120014978A1 (en) 2012-01-19
NZ593145A (en) 2013-01-25
EP2373293B2 (en) 2016-06-01
JP2015057383A (ja) 2015-03-26
ES2427855T5 (es) 2016-06-28
JP5612592B2 (ja) 2014-10-22
CN102227214B (zh) 2015-02-18
US20160367660A1 (en) 2016-12-22
EP2373293A2 (en) 2011-10-12
IL213088A (en) 2017-01-31
SI2373293T1 (sl) 2013-11-29
EA201100865A1 (ru) 2011-12-30
WO2010061193A3 (en) 2011-06-23
GB201114575D0 (en) 2011-10-05
WO2010061193A2 (en) 2010-06-03
CN102227214A (zh) 2011-10-26
GB2479515B (en) 2013-05-22
CA2744587A1 (en) 2010-06-03
IL213088A0 (en) 2011-07-31
EP2373293B8 (en) 2013-09-18
SG171438A1 (en) 2011-07-28
DK2373293T3 (da) 2013-10-07
HK1161139A1 (en) 2012-08-24
EP2373293B1 (en) 2013-07-31
AU2009321358B2 (en) 2015-06-18
BRPI0921541A2 (pt) 2016-04-26
US9375470B2 (en) 2016-06-28
MX2011005530A (es) 2011-06-06
US9180098B2 (en) 2015-11-10
GB2479515A (en) 2011-10-12

Similar Documents

Publication Publication Date Title
GB2479515B (en) Compositions with reduced dimer formation
SI2634231T1 (sl) Sestavki
GB0810404D0 (en) Compositions
ZA201103926B (en) Stable sulfoximine-insecticide compositions
GB0812041D0 (en) Compositions
GB0810554D0 (en) Herbicde composition
GB0801119D0 (en) Composition
GB0808537D0 (en) Compositions
GB0818804D0 (en) Compositions
GB0809808D0 (en) Composition
GB0811743D0 (en) Composition
GB0801401D0 (en) Composition
GB0810359D0 (en) Composition
GB0806948D0 (en) Composition
GB0809983D0 (en) Composition
GB0804031D0 (en) Composition
GB0812197D0 (en) Compositions
GB0805099D0 (en) Claening compositions
GB0822112D0 (en) Compositions
GB0800412D0 (en) Compositions
GB0818050D0 (en) Compositions
GB0809354D0 (en) Compositions
GB0803186D0 (en) Composition
GB0807594D0 (en) Composition
GB0807568D0 (en) Composition